Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
:HALO
Total Valuation
Halozyme has a market cap or net worth of $8.24B. The enterprise value is $9.78B.
Market Cap$8.24B
Enterprise Value$9.78B
Share Statistics
Halozyme has 117,597,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding117,597,000
Owned by Insiders1.15%
Owned by Institutions14.57%
Financial Efficiency
Halozyme’s return on equity (ROE) is 1.22 and return on invested capital (ROIC) is 22.84%.
Return on Equity (ROE)1.22
Return on Assets (ROA)0.22
Return on Invested Capital (ROIC)22.84%
Return on Capital Employed (ROCE)0.29
Revenue Per Employee2.90M
Profits Per Employee1.27M
Employee Count350
Asset Turnover0.49
Inventory Turnover1.12
Valuation Ratios
The current PE Ratio of Halozyme is 14.7. Halozyme’s PEG ratio is 0.21.
PE Ratio14.7
PS Ratio5.97
PB Ratio16.67
Price to Fair Value16.67
Price to FCF12.95
Price to Operating Cash Flow13.09
PEG Ratio0.21
Income Statement
In the last 12 months, Halozyme had revenue of 1.02B and earned 444.09M in profits. Earnings per share was 3.50.
Revenue1.02B
Gross Profit855.91M
Operating Income551.48M
Pretax Income557.13M
Net Income444.09M
EBITDA656.54M
Earnings Per Share (EPS)3.50
Cash Flow
In the last 12 months, operating cash flow was 611.00M and capital expenditures -8.60M, giving a free cash flow of 602.40M billion.
Operating Cash Flow611.00M
Free Cash Flow602.40M
Free Cash Flow per Share5.12
Dividends & Yields
Halozyme pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.42
52-Week Price Change64.51%
50-Day Moving Average70.27
200-Day Moving Average62.32
Relative Strength Index (RSI)58.20
Average Volume (3m)2.23M
Important Dates
Halozyme upcoming earnings date is Feb 24, 2026, After Close (Confirmed).
Last Earnings DateNov 3, 2025
Next Earnings DateFeb 24, 2026
Ex-Dividend Date―
Financial Position
Halozyme as a current ratio of 7.80, with Debt / Equity ratio of 299.80%
Current Ratio7.80
Quick Ratio6.78
Debt to Market Cap0.25
Net Debt to EBITDA2.12
Interest Coverage Ratio30.48
Taxes
In the past 12 months, Halozyme has paid 113.04M in taxes.
Income Tax113.04M
Effective Tax Rate0.20
Enterprise Valuation
Halozyme EV to EBITDA ratio is 11.35, with an EV/FCF ratio of 15.91.
EV to Sales7.34
EV to EBITDA11.35
EV to Free Cash Flow15.91
EV to Operating Cash Flow15.56
Balance Sheet
Halozyme has $701.96M in cash and marketable securities with $1.51B in debt, giving a net cash position of -$808.79M billion.
Cash & Marketable Securities$701.96M
Total Debt$1.51B
Net Cash-$808.79M
Net Cash Per Share-$6.88
Tangible Book Value Per Share-$3.59
Margins
Gross margin is 84.55%, with operating margin of 54.32%, and net profit margin of 43.74%.
Gross Margin84.55%
Operating Margin54.32%
Pretax Margin54.87%
Net Profit Margin43.74%
EBITDA Margin64.66%
EBIT Margin56.65%
Analyst Forecast
The average price target for Halozyme is $80.71, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$80.71
Price Target Upside15.25% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast31.19%
EPS Growth Forecast59.01%